Male hormonal contraceptives: a potentially patentable and profitable product

  title={Male hormonal contraceptives: a potentially patentable and profitable product},
  author={Paul B. Cornia and B. Anawalt},
  journal={Expert Opinion on Therapeutic Patents},
  pages={1727 - 1737}
  • Paul B. Cornia, B. Anawalt
  • Published 2005
  • Medicine
  • Expert Opinion on Therapeutic Patents
  • Although women have traditionally shouldered the responsibility of contraception, up to one-third of couples worldwide employ a male form of contraception (e.g., vasectomy or condoms). Vasectomy should be considered irreversible and long-term use of condoms is associated with a relatively high failure rate (pregnancy). Because many women are unable to use hormonal contraception and men want more contraceptive options, there is a need for a safe, effective, reversible and well-tolerated male… CONTINUE READING
    2 Citations


    Contraceptive efficacy of a depot progestin and androgen combination in men.
    • 64
    • Highly Influential
    A review of androgen-progestin regimens for male contraception.
    • 41
    Clinical trial of transdermal testosterone and oral levonorgestrel for male contraception.
    • 93
    • PDF
    Potential impact of hormonal male contraception: cross-cultural implications for development of novel preparations.
    • 180
    • PDF
    Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception.
    • 118
    • PDF
    An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations.
    • 120
    • PDF